Biopharma companies that elect not to provide access to their investigational medicines under the new right-to-try law should publicly post their policies to help protect themselves from “naming and shaming” by unhappy patients, experts say.
Since the right-to-try law has removed FDA as a gatekeeper to preapproval access, companies will now bear all the blame...






